中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

23 records (took 0.028 seconds)

    MAGNETIC SEPARATION OF FINE PARTICLES FROM COMPOSITIONS
    1.
    发明申请
    MAGNETIC SEPARATION OF FINE PARTICLES FROM COMPOSITIONS 审中-公开
    从组合物中精细分离细颗粒的磁分离

    公开(公告)号：WO2008080047A3

    公开(公告)日：2008-08-14

    申请号：PCT/US2007088527

    申请日：2007-12-21

    Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  KIPP JAMES E ,  WONG JOSEPH CHUNG TAK ,  WERLING JANE O

    Inventor： KIPP JAMES E ,  WONG JOSEPH CHUNG TAK ,  WERLING JANE O

    IPC: B03C1/28

    CPC classification number: B03C1/288

    Abstract: The disclosure describes apparatuses and methods of use thai may be used to remove material with magnetic properties from compositions, particularly pharmaceutical compositions. The apparatuses provide a conduit or column in which a magnetic field exists and through which a composition flows. Magnetic material in the composition is substantially reduced after flowing through the conduit or column.

    Abstract translation: 本公开描述了可以用于从组合物，特别是药物组合物中去除具有磁性的材料的装置和方法。 这些装置提供了一种导管或立柱，其中存在磁场并且组合物通过该磁场流动。 组合物中的磁性材料在流过导管或柱之后显着降低。

    METHOD FOR DELIVERING PARTICULATE DRUGS TO TISSUES
    5.
    发明申请
    METHOD FOR DELIVERING PARTICULATE DRUGS TO TISSUES 审中-公开
    将颗粒药物递送给组织的方法

    公开(公告)号：WO2007124224A2

    公开(公告)日：2007-11-01

    申请号：PCT/US2007/064679

    申请日：2007-03-22

    Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE S.A. ,  RABINOW, Barrett, E. ,  GENDELMAN, Howard, E. ,  KIPP, James, E.

    Inventor： RABINOW, Barrett, E. ,  GENDELMAN, Howard, E. ,  KIPP, James, E.

    IPC: A61K9/00 ,  A61K9/51 ,  A61K47/48

    CPC classification number: A61K9/0085 ,  A61K9/10 ,  A61K9/5123 ,  A61K9/5146 ,  A61K47/6901

    Abstract: The present invention is concerned with delivering a pharmaceutical composition to a tissue target of a mammalian subject for treating brain diseases or disorders. The process includes the steps of: (i) providing a dispersion of the pharmaceutical composition as particles having an average particle size of from about 150 nm to about 100 microns, and (ii) administering the dispersion to the mammalian subject for delivery to the tissue target of a portion of the pharmaceutical composition by cells capable of reaching the tissue target. The dispersion of the pharmaceutical composition as particles, for example, can be phagocytised or adsorbed by the cells prior or subsequent to administration into the mammalian subject. The dispersion of the pharmaceutical composition can be administered to the central nervous system or the vascular system. After administration, the loaded cells transport the pharmaceutical composition as particles into the tissue target.

    Abstract translation: 本发明涉及将药物组合物递送至哺乳动物受试者的组织靶以治疗脑部疾病或病症。 该方法包括以下步骤：（i）提供药物组合物的分散体作为平均粒度为约150nm至约100微米的颗粒，和（ii）向哺乳动物受试者施用分散体以递送至组织 通过能够到达组织靶的细胞的一部分药物组合物的靶标。 例如，作为颗粒的药物组合物的分散体可以在给予哺乳动物受试者之前或之后被细胞吞噬或吸附。 药物组合物的分散体可以施用于中枢神经系统或血管系统。 给药后，负载的细胞将药物组合物作为颗粒输送到组织靶中。

    (POLYALKOXY)SULFONATE SURFACE MODIFIERS
    6.
    发明申请
    (POLYALKOXY)SULFONATE SURFACE MODIFIERS 审中-公开
    （聚烷氧基）磺酸盐表面改性剂

    公开(公告)号：WO2006081000A2

    公开(公告)日：2006-08-03

    申请号：PCT/US2005/045321

    申请日：2005-12-15

    Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE S.A. ,  KIPP, James E. ,  HAI, Ton That ,  MELNICK, Bennett, P.

    Inventor： KIPP, James E. ,  HAI, Ton That ,  MELNICK, Bennett, P.

    IPC: C08G65/326 ,  C08G65/334 ,  C08L71/02

    CPC classification number: C08G65/334 ,  A61K8/90 ,  A61K9/146 ,  A61K47/34 ,  A61Q19/00 ,  C08G65/326 ,  C08L71/02

    Abstract: The present invention is directed to novel compounds, methods of manufacture and methods of use. The present invention is also directed to solid drug/active agent particles having one or more of the compounds of the present invention associated with the surface thereof. The compounds of the present invention are comprised of a non-polar polyether covalently linked to an anionic sulfonate group. The compounds have an amphipathic quality and preferably, are surface active. Such compounds are preferably useful as surface-active agents to coat and stabilize dispersions of particles in a continuous liquid medium. These surface-active agents may be applied in the stabilization of suspensions, emulsions, or liposome formulations intended for pharmaceutical, medical, cosmetic, or agricultural use. The particles that can be prepared by a variety of methods and will preferably comprise a pharmaceutical agent. Pharmaceutical compositions of the present invention can be used to treat amyriad of conditions and can be administered by many routes, including intravenous, intramuscular, subcutaneous, intrathecal, subdural, intracameral, intracerebral, intralesional, topical, oral, buccal, rectal, pulmonary, and nasal.

    Abstract translation: 本发明涉及新化合物，制造方法和使用方法。 本发明还涉及具有与其表面结合的一种或多种本发明化合物的固体药物/活性剂颗粒。 本发明的化合物由与阴离子磺酸盐基团共价连接的非极性聚醚组成。 这些化合物具有两亲性，并且优选具有表面活性。 这些化合物优选用作表面活性剂以涂覆和稳定连续液体介质中的颗粒分散体。 这些表面活性剂可以用于稳定用于药物，医学，化妆品或农业用途的悬浮液，乳液或脂质体制剂。 可以通过多种方法制备并且优选包含药剂的颗粒。 本发明的药物组合物可用于治疗多种病症，并可通过多种途径给药，包括静脉内，肌肉内，皮下，鞘内，硬膜下，前房内，脑内，病灶内，局部，口服，口腔，直肠，肺和 鼻

    METHOD FOR PREPARING SMALL PARTICLES
    9.
    发明申请
    METHOD FOR PREPARING SMALL PARTICLES 审中-公开
    制备小颗粒的方法

    公开(公告)号：WO2004082659A1

    公开(公告)日：2004-09-30

    申请号：PCT/US2004/005696

    申请日：2004-02-25

    Applicant: BAXTER INTERNATIONAL INC. ,  KIPP, James, E. ,  WONG, Joseph, Chung, Tak ,  WERLING, Jane ,  REBBECK, Christine, L. ,  BRYNJELSEN, Sean

    Inventor： KIPP, James, E. ,  WONG, Joseph, Chung, Tak ,  WERLING, Jane ,  REBBECK, Christine, L. ,  BRYNJELSEN, Sean

    IPC: A61K9/10

    CPC classification number: A61K31/495 ,  A61K9/10 ,  A61K9/14 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1682 ,  A61K9/1688 ,  A61K31/12 ,  A61K31/337 ,  A61K31/496 ,  A61K31/55 ,  A61K31/573

    Abstract: The present invention is concerned with the formation of small particles or organic compounds by precipitating the organic compounds in an aqueous medium to form a pre-suspension followed by adding energy to stabilize a coating of the particle or to alter the lattice structure of the particle. The process includes the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution; (ii) mixing the solution with the second solvent to define a presuspension of particles; and (iii) adding energy to the presuspension to form a suspension of particles having an average effective particle size of less than about 100 μm. The process is preferably used to prepare a suspension of small particles of a poorly water-soluble, pharmaceutically active compound suitable for in vivo delivery by an administrate route such as parenteral, oral, pulmonary, nasal, buccal, topical ophthalmic, rectal, vaginal, transdermal or the like.

    Abstract translation: 本发明涉及通过在水性介质中沉淀有机化合物以形成预悬浮液，然后加入能量以稳定颗粒的涂层或改变颗粒的晶格结构来形成小颗粒或有机化合物。 该方法包括以下步骤：（i）将有机化合物溶解在水混溶的第一溶剂中以形成溶液; （ii）将溶液与第二溶剂混合以限定颗粒的预悬浮液; 和（iii）向预悬浮液中加入能量以形成平均有效粒径小于约100μm的颗粒的悬浮液。 该方法优选用于制备适用于通过给药途径（例如肠胃外，口服，肺，鼻，口腔，局部眼科，直肠，阴道，阴道内）的体内递送的难溶于水的药学活性化合物的小颗粒的悬浮液， 透皮等。

    COMPOSITIONS OF LIPOXYGENASE INHIBITORS
    10.
    发明申请
    COMPOSITIONS OF LIPOXYGENASE INHIBITORS 审中-公开
    LIPOXYGENASE抑制剂的组合物

    公开(公告)号：WO2007059515A2

    公开(公告)日：2007-05-24

    申请号：PCT/US2006/060939

    申请日：2006-11-15

    Applicant: BAXTER INTERNATIONAL, INC. ,  BAXTER HEALTHCARE S.A. ,  KIPP, James, E. ,  WERLING, Jane ,  GUPTA, Pramod ,  BURESH, Rita

    Inventor： KIPP, James, E. ,  WERLING, Jane ,  GUPTA, Pramod ,  BURESH, Rita

    IPC: A61K9/24 ,  A61K9/19 ,  A61K31/381 ,  A61P1/00 ,  A61P9/10 ,  A61P11/06

    CPC classification number: A61K9/10 ,  A61K9/0043 ,  A61K9/0048 ,  A61K9/19 ,  A61K9/5146 ,  A61K31/38 ,  A61K31/381

    Abstract: Pharmaceutical compositions comprising particles of lipoxygenase inhibitor compounds having an effective average size of from about 10 nm to about 50 microns are provided. More particularly, pharmaceutical compositions of particle of a 5 -lipoxygenase inhibitor compound having an effective average size of from about 50 nm to about 5 microns are provided. The pharmaceutical compositions are in the form of aqueous suspensions with the particle of the 5-lipoxygenase-inhibitor compound present in concentrations of from about 5 to about 200 mg/ml. In addition, methods for making such pharmaceutical compositions are provided. In particular, microprecipitation and direct homogenization in the presence of at least one surfactant are disclosed for making the pharmaceutical compositions.

    Abstract translation: 提供了包含具有约10nm至约50微米的有效平均尺寸的脂氧合酶抑制剂化合物颗粒的药物组合物。 更具体地，提供了具有约50nm至约5微米的有效平均尺寸的5-脂氧合酶抑制剂化合物的颗粒的药物组合物。 药物组合物为水性悬浮液的形式，其中5-脂氧合酶抑制剂化合物的颗粒以约5至约200mg / ml的浓度存在。 此外，提供了制备这种药物组合物的方法。 特别地，公开了在至少一种表面活性剂存在下的微沉淀和直接均化，用于制备药物组合物。

Patent Agency Ranking